First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort

Galvin, Angéline; Courtinard, Coralie; Bouteiller, Fanny; Gourgou, Sophie; Dalenc, Florence; Jacot, William; Arnedos, Monica; Bailleux, Caroline; Dieras, Véronique; Petit, Thierry; Emile, George; Dubray-Longeras, Pascale; Frenel, Jean-Sébastien; Bachelot, Thomas; Mailliez, Audrey; Brain, Etienne; Desmoulins, Isabelle; Massard, Vincent; Patsouris, Anne; Goncalves, Anthony; Grinda, Thomas; Delaloge, Suzette; Bellera, Carine

doi:10.1016/j.ejca.2023.113422

European Journal of Cancer

2024

DOI: 10.1016/j.ejca.2023.113422

|View full text |Cite

First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort

Angéline Galvin,

Coralie Courtinard,

Fanny Bouteiller

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

2025

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 5 publications

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Enhancing the Safety and Efficacy of Trastuzumab Emtansine (T‐DM1) Through Nano‐Delivery System in Breast Cancer Therapy

Liu,

Mao,

Chen

et al. 2024

Small

View full text Add to dashboard Cite

Trastuzumab emtansine (T‐DM1), an antibody‐drug conjugate, revolutionizes breast cancer therapy by specifically delivering DM1 to human epidermal growth factor receptor 2 (HER2) overexpressing tumor cells, effectively inhibiting cell division and proliferation. While T‐DM1 demonstrates superior efficacy and tolerability, T‐DM1‐induced thrombocytopenia remains a significant adverse event leading to treatment discontinuation. To address this issue, the study investigates the feasibility of using poly(lactic‐co‐glycolic acid) (PLGA) nanoparticles as a delivery vehicle to conjugate T‐DM1, aiming to alleviate T‐DM1‐induced thrombocytopenia. The T‐DM1‐conjugated PLGA nanoparticles (NPs‐T‐DM1) reduce binding to megakaryocytes without compromising the targeting ability for HER2. Administration of NPs‐T‐DM1 not only significantly inhibits tumor growth but also reduces damage to megakaryocytes, inhibits T‐DM1‐induced thrombocytopenia, and remarkably improves the safety of antibody‐conjugated drugs. This work presents a promising strategy to enhance the safety and efficacy of T‐DM1 in antitumor therapy, offering significant potential for advancing clinical application in HER2‐positive breast cancer patients.

show abstract

Enhancing the Safety and Efficacy of Trastuzumab Emtansine (T‐DM1) Through Nano‐Delivery System in Breast Cancer Therapy

Liu,

Mao,

Chen

et al. 2024

Small

View full text Add to dashboard Cite

show abstract

Pre-treatment [18F]FDG PET/CT biomarkers for the prediction of antibody–drug conjugates efficacy in metastatic breast cancer

Seban,

Champion,

De Moura

et al. 2024

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Treatment sequences and survival outcomes in advanced HR + HER2- breast cancer patients: a real-world cohort

Almekinders,

Lin,

Beijnen

et al. 2024

Breast Cancer Res Treat

View full text Add to dashboard Cite

Purpose Palliative treatment options for HR + HER2- advanced breast cancer (ABC) patients have increased, but data is lacking about the optimal treatment sequence. We used real-world data from a comprehensive cancer center to describe applied treatment sequences and we determined treatment-related and survival outcomes. Methods Patients aged 18 years and older with HR + HER2- ABC treated with systemic treatment were included in this historic cohort study. Sequential treatment schedules, time to treatment discontinuation, time to chemotherapy, and overall survival (OS) were determined, stratified by first-line treatment. Results 202 patients were included. They received a total of 650 treatment lines (median 3; range: 1–11). 91 (45%), 25 (12%), 24 (12%), 28 (14%), 22 (11%) and 12 (6%) patients started first-line treatment with non-steroidal aromatase inhibitors (NSAI), NSAI + cyclin dependent kinase 4/6-inhibitors (CDK4/6i), fulvestrant + CDK4/6i, tamoxifen, chemotherapy and other treatment, respectively. 10, 13, and 14 different treatment regimens were given in first, second and third-line, respectively. Of the patients who started first-line NSAI monotherapy (n = 91), 3 (3%) died before receiving second-line treatment. Conclusion In this real-world cohort, we observed a wide variety of different treatment sequences applied in daily clinical practice, some of which were in discordance with the current guidelines. Fear that patients may never get around to treatment with CDK4/6i if a patient did not start with a CDK4/6i was not supported by our study results.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort

Cited by 5 publications

References 35 publications

Enhancing the Safety and Efficacy of Trastuzumab Emtansine (T‐DM1) Through Nano‐Delivery System in Breast Cancer Therapy

Enhancing the Safety and Efficacy of Trastuzumab Emtansine (T‐DM1) Through Nano‐Delivery System in Breast Cancer Therapy

Pre-treatment [18F]FDG PET/CT biomarkers for the prediction of antibody–drug conjugates efficacy in metastatic breast cancer

Treatment sequences and survival outcomes in advanced HR + HER2- breast cancer patients: a real-world cohort

Contact Info

Product

Resources

About